25 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00125 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 2.7% inhibition at 10-6 M |
| dbacp00126 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 2.0% inhibition at 10-5 M |
| dbacp00127 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 18.8% inhibition at 10-4 M |
| dbacp00128 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HEp-2 | Larynx cancer | 26.7% inhibition at 10-3 M |
| dbacp00129 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 9.8% inhibition at 10-6 M |
| dbacp00130 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 7.3% inhibition at 10-5 M |
| dbacp00131 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 9.9% inhibition at 10-4 M |
| dbacp00132 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HeLa | Cervical cancer | 28.2% inhibition at 10-3 M |
| dbacp00133 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 1.6% inhibition at 10-6 M |
| dbacp00134 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 2.9% inhibition at 10-5 M |
| dbacp00135 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 5.9% inhibition at 10-4 M |
| dbacp00136 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HBL | Skin cancer | 17.9% inhibition at 10-3 M |
| dbacp00137 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 5.4% inhibition at 10-6 M |
| dbacp00138 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 7.4% inhibition at 10-5 M |
| dbacp00139 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 9.5% inhibition at 10-4 M |
| dbacp00140 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | HT-29 | Colon cancer | 15.7% inhibition at 10-3 M |
| dbacp00141 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 13.6% inhibition at 10-6 M |
| dbacp00142 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 20.4% inhibition at 10-5 M |
| dbacp00143 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 14.4% inhibition at 10-4 M |
| dbacp00144 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | SW-620 | Colon cancer | 23.4% inhibition at 10-3 M |
| dbacp00145 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 2.2% inhibition at 10-6 M |
| dbacp00146 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 4.2% inhibition at 10-5 M |
| dbacp00147 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 6.4% inhibition at 10-4 M |
| dbacp00148 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | CaCo-2 | Colon cancer | 6.2% inhibition at 10-3 M |
| dbacp00149 | Enkephalins7 analogue-15 | YSA*G | Synthetic Peptide | Apoptosis inducing | MTT/MTS assay | MCF-7 | Breast cancer | 21.2% inhibition at 10-3 M |